Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Urothelial Cancer · Advanced/Metastatic Urothelial Cancer · Urothelial Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 132 (planned)
- Started
- Mar 11, 2026
- Main results expected
- Dec 28, 2027
- Fully finished
- Sep 25, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed Objective Response Rate (ORR) by investigator
Measured over: Up to approximately 3 years
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: Through 90 days after the last study intervention; Up to approximately 3 years
Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort B
Measured over: Through 90 days after the last study intervention; Up to approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07421700 · record last updated 2026-10-08 · checked 2026-11-09 15:42 UTC